Qualitative Conceptual Content Analysis of COVID-19 Vaccine Administration Error Inquiries-Reference-Cited by-同舟云学术

Qualitative Conceptual Content Analysis of COVID-19 Vaccine Administration Error Inquiries

Published:2023-01-24 Issue:2 Volume:11 Page:254
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Hall Elisha¹^ORCID,Odafe Solomon¹,Madden Joseph²^ORCID,Schillie Sarah¹

Affiliation:

1. Communication and Education Branch, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A-19, Atlanta, GA 30329-4027, USA

2. ASPPH/CDC Public Health Fellow (Embedded in Communication and Education Branch, Immunization Services Division, National Center for Immunization and Respiratory Diseases), Centers for Disease Control and Prevention, 1600 Clifton Rd, MS A-19, Atlanta, GA 30329-4027, USA

Abstract

The launch of the COVID-19 vaccination program was the largest vaccination campaign in U.S. history, with an unprecedented demand for vaccine and new vaccination providers, warranting significant education and communication efforts. NIP-INFO (nipinfo@cdc.gov) is the Centers for Disease Control and Prevention’s (CDC’s) immunization inquiry response service, and it receives inquiries for COVID-19 and routine non-COVID vaccines. A qualitative analysis of NIP-INFO’s content was performed to better characterize and understand some of the knowledge gaps and reasons that COVID-19 vaccine administration errors occur. A total of 734 COVID-19 vaccine administration error inquiries were received between January 2021 and April 2022. The most frequent inquiries related to storage (n = 191; 26.0%), incorrect dosage or product (n = 190; 25.9%), unauthorized age group (n = 108; 14.7%), and schedule (n = 105; 14.3%). Training and communication strategies are imperative to ensure proper vaccine administration and build and maintain vaccine confidence.

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/2/254/pdf

Reference47 articles.

1. U.S. Food and Drug Administration (2020). FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine, U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration (2020). FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine, U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration (2021). FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine, U.S. Food and Drug Administration.

4. U.S. Department of Health and Human Services (2021). Eighth Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, U.S. Department of Health and Human Services.

5. U.S. Department of Health and Human Services (2021). Ninth Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19, U.S. Department of Health and Human Services.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDC COVID-19 vaccination program: Healthcare provider compliance with COVID-19 vaccine requirements and recommendations;Vaccine;2023-12